Proteomic data in meningiomas: post-proteomic analysis can reveal novel pathophysiological pathways
- 331 Downloads
Meningiomas account for approximately 20% of adult primary intracranial tumours. WHO I meningiomas are the most common and are generally benign, but can progress, recur or transform to WHO II or WHO III grades over many years. A systematic review of multiple independent shotgun proteomic analyses of meningioma was performed to provide insight into underlying disease pathways. Shotgun proteomics has been conducted in seven meningioma related studies but there is considerable variation in aims, methodology, statistical power and the use of control tissue between these studies. Fifteen proteins which are different between WHO I and WHO II meningiomas and nine proteins which are different between WHO II and WHO III meningiomas have been described but without a view of their biological significance. Network analysis of proteins different between WHO I and WHO II meningiomas provided a coherent hypothesis for the involvement of these proteins in meningioma. Western blot analyses of meningioma tissue provided a measure of support for a core component in the network (involving VDAC2, APOA1 and HNF4α) but highlighted intrinsic difficulty of proteomic and biochemical analysis of meningiomas (as a consequence of gross alterations in tissue composition). Systematic review of shotgun proteomics and network analysis provides insight into meningioma pathophysiology despite the many barriers and difficulties that are inherent to this type of study.
KeywordsMeningioma Proteomics Pathophysiology Functional network
This work was partly supported by grants from the Chief Scientists Office, the Melville Trust, and The Brain Tumour Research Fund.
- 4.Perry A, Louis D, Scheithauer B, Budka H, Von Deimling A (2007) Meningiomas. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system. IARC press, Lyon, pp 164–172Google Scholar
- 9.Deighton R, McGregor R, Kemp J, McCulloch J, Whittle I (2010) Glioma pathophysiology: insights emerging from proteomics. Brain Pathol 1015–6305:1–13Google Scholar
- 10.Ingenuity systems citing guidelines. Last updated 2009. Available from http://www.ingenuity.com
- 17.Saydam O, Senol O, Schaaij-Visser T, Pham T, Piersma S, Stemmer-Rachamimov A, Wurdinger T, Peerdeman S, Jimenez C (2010) Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas. J Proteome Res 9:485–494PubMedCrossRefGoogle Scholar
- 18.Scholz M (2006) Proteomics-based identification of differentially expressed proteins in human meningiomas. German medical science (Meeting Abstract)Google Scholar